OxyPrem on Swiss National Television (SRF, "10 vor 10")
Aired Nov 1st, 2024
OxyPrem at "10 vor 10", with crowd campaign incentive
November 2024
OxyPrem will be featured on the popular TV news magazine "10 vor 10" on Swiss station "SRF 1" on November 1st, 21:50 CET. Tune in for an OxyPrem "behind the scenes" and to see our OxyPrem 1.4 system outside the typical ICU application - in music therapy!
.
After its airtime, the broadcast can also be watched at https://www.srf.ch/play/tv/sendung/10-vor-10?id=c38cc259-b5cd-4ac1-b901-e3fddd901a3d (in German/Swiss German language), even from outside Switzerland.
.
To reflect this in our crowd investing campaign at https://capitalcell.com/en/campaign/oxyprem/ , the following "10-themed" incentive is now active on the campaign website:
OxyPrem featured on "10 vor 10"...
...therefore, investments of at least 5.000 EUR receive a 10% reduction in share price
incentive runs until November 10th.
Information for current investors:
If you already have invested 5.000 EUR or more, you will be contacted by Capital Cell to adapt to the new conditions.
If you want to increase your existing investment to 5.000 EUR or more, you receive the 10% reduction on your entire investment. Please write to campaign@oxyprem.com - the OxyPrem and Capital Cell teams will help you with the process.
Become an OxyPrem investor today and help us protect the brains of high-risk patients!
Crowdinvesting campaign hits 70% and approaches 100 investors
October 2024
Our crowd investment campaign, running on https://capitalcell.com/en/campaign/oxyprem/, is progressing. 70% of the campaign goal has been committed, and the campaign is soon to cross the 100-investor mark.
.
Additionally, the Capital Cell team invited our CEO Alexander Nitsch to an interview in their "Meet the Founder" video series. The video is available in English with subtitles in various languages at https://www.youtube.com/watch?v=bXHAKPfnukM .
.
Invest in OxyPrem today and become part of our journey!
Crowdinvesting campaign enters live stage
September 2024
Our crowdinvesting campaign at https://capitalcell.com/en/campaign/oxyprem/ has entered live stage, that is: Reservations can now be converted into investments, and also, direct investments by new visitors are possible.
For investments before September 18th, a 2.8% discount on the share price is applied.
For investments over EUR 15'000 (and investments coming from the reservation phase), a 6.5% discount on the share price is applied.
Join us today and become an OxyPrem shareholder!
OxyPrem featured in Ticino Management
August 2024
The Ticino Management magazine has published a great feature article about OxyPrem for its "Eureka" series (in Italian language).
Enjoy the read! https://www.eidosmedia.ch/it/ticino-management/ossigenare-linnovazione/
Call to action: OxyPrem crowd investing campaign!
August 2024
Support our crowd investing campaign, to help OxyPrem protect the weakest patients with our second generation of brain oxygen sensors!
Full campaign website: https://capitalcell.com/en/campaign/oxyprem/ .
Short memo with initial information: https://extern.cloud.oxyprem.com/s/HYNCY2t7BwxYwSQ
Join the campaign and reserve your investment in OxyPrem today!
UK roadshow
July 2024
The OxyPrem team will conduct a roadshow in and around London, UK, during the week of July 22nd to July 26th. We are open for additional visits to clinical users as well as companies interested in partnering. Please do not hesitate to get in touch!
Design Review 2 for NOAH completed
June 2024
The OxyPrem team is happy to announce that Design Review 2, one of the key milestones en route to MDR CE mark for OxyPrem NOAH, has been successfully completed.
Third patent granted
June 2024
The OxyPrem team is glad to announce that a third patent has been granted. It belongs to the Usability block of patent filings.
This patent follows the first two of our patent portfolio, which have been granted in the USA and China as well as in Europe, respectively.
Quality-focused patent granted in Europe
May 2024
The OxyPrem team is proud to announce that an additional patent (scope: quality / durability / longevity) has been granted in Europe. This follows the granting of our first patent in the USA and China.
OxyPrem at ISOTT 2024
May 2024
Heading for Socorro, New Mexico, Dr. Alexander Kalyanov will participate at the 2024 of the International Society for Oxygen Transport to Tissue (ISOTT). The event takes place from June 9th to 14th.
We are looking forward to interesting insights and discussions!
OxyPrem at Startupdays 2024
May 2024
Our CEO Alexander Nitsch will be present at this year's Startupdays (SUD) in Bern on May 30th. We are actively seeking conversations with investors and strategic partners.
See you in Bern!
OxyPrem supports multinational clinical trial
March 2024
A consortium of Imperial College (London, UK), Gupta Neonatal Hospital (Hisar, India), and Azienda ospedaliera Luigi Vanvitelli (Naples, Italy) has chosen OxyPrem 1.4 to perform the clinical trial "Physiological responses to intravenous caffeine in neonates with Hypoxic Ischaemic Encephalopathia".
We are excited to support the medical teams and are looking forward to the collaboration!
Singapore funding roadshow
February 2024
In the first week of February, an OxyPrem representative will be in Singapore to meet potential investors and strategic partners. If you are interested in scheduling a meeting, please reach out to us. Thank you!
OxyPrem at MEDICA 2023
November 2023
Our CEO Alexander Nitsch will visit MEDICA 2023 in Düsseldorf, Germany, on November 15th to meet potential investors, strategic partners, and existing suppliers. The OxyPrem 1.4 tissue oximetry system will be on display at the booth of Phoenix Medical Systems.
Please reach out to us to arrange a meeting!
OxyPrem selected for UK medtech mission
October 2023
From October 16th to 19th, OxyPrem will be part of the UK Mission for Swiss Medtech Startups, organized jointly by the Swiss and UK administrations. Following a 3-day programme in London, there will also be a hands-on clinical day in Leeds.
We (Clinical Specialist Paul Hampson, Leeds chapter and CEO Alexander Nitsch, London chapter) are looking forward to attending!
OxyPrem explores crowdlending
September 2023
The team would be happy to welcome you amongst the backers on this project website!
OxyPrem has launched a crowdlending campaign with our partner swisspeers ag.
Belgium and Netherlands clinical roadshow
September 2023
In the week starting September 11th, OxyPrem is planning on-site visits to neonatal intensive care units (NICUs) in Belgian and Dutch centers. Please feel free to reach out to us, in case you would like to arrange a meeting or product demonstration.
OxyPrem as double runner-up
May 2023
Both at the Life Science Zurich Impact Conference and at the Startupdays, OxyPrem finished politely in second place of the pitch battles in our respective verticals.
Thank you to everyone who attended the pitches and to the juries and audiences!
OxyPrem at Arab Health 2023
January 2023
From Jan 30th to Feb 2nd, OxyPrem will co-exhibit at Arab Health 2023 with our partners of Phoenix Medical Systems. We are looking forward to many visitors at booth Z4.F49!
OxyPrem at Neonatal Neurology Symposium
January 2023
From On January 27th, the OxyPrem team will attend the 24th edition of the Neonatal Neurology Symposium in Maastricht, The Netherlands, with an own booth and OxyPrem equipment present on-site.
We are looking forward to present OxyPrem to a highly dedicated and inspiring audience!
OxyPrem at Neocon 2022
December 2022
From Dec 1st to Dec 4th, OxyPrem will co-exhibit at Neocon 2022 in Calcutta, India. The team is excited to explore partnerships and get in touch with interested hospital chains and health centres.
OxyPrem at INFANT symposium in Ireland
November 2022
OxyPrem sponsors the Research Symposium in Clinical Trials in Neonatology in Cork, Ireland, on Nov 25th. A full OxyPrem system will be present at the booth, for all interested clinicians to get first-hand impressions on the OxyPrem solutions.
OxyPrem at EAPS 2022
October 2022
Come visit us at our booth no. 43 at EAPS 2022 in Barcelona! We will be present from Oct 6th to Oct 10th and are looking forward to meet you, have interesting conversations, and show our solutions to you.
OxyPrem wins 2nd place at Swiss Excellence Award
September 2022
For more details see our LinkedIn profile and the foundation website.
In a close call, OxyPrem finished as the runner-up at the Swiss Excellence Award finals 2022. We are very proud, and thanks to our great team, more successes are hopefully coming soon!
OxyPrem now ISO 13485 certified
August 2022
For more details see our LinkedIn profile.
The OxyPrem team is proud to announce that our quality management system is now ISO 13485:2016 certified!
OxyPrem obtains CHF 2.2 million grant
January 2022
See SERI's official information HERE. Thank you very much to the EU evaluators and to the great members of SERI for joining us on our path!
OxyPrem has obtained a large SERI-funded EIC Accelerator grant. After a positive EU evaluation of the OxyPrem proposal last year, the Secretariat for Education, Research and Innovation (SERI) decided to cover the grants for the Swiss applicants as direct EU funding was not possible.
OxyPrem onboards EC Representative
January 2022
Our team is very happy and looking forward to a great collaboration!
OxyPrem has initiated cooperation with EUSwissMed GmbH. EUSwissMed is an authorized EC Representative with long years of experience in the regulatory field.
OxyPrem wins another Seal of Excellence
November 2020
Once again thank you to the EU!
For the second time, OxyPrem was awarded the EU Seal of Excellence for outstanding projects.
OxyPrem featured in EU publication
August 2020
The European Union has written a feature article on OxyPrem. It is available in six languages via the following link: CLICK.
OxyPrem wins EU Seal of Excellence
May 2020
Thank you to the EU for this strong encouragement!
OxyPrem was awarded the Seal of Excellence by the European Union's Accelerator program (SME Instrument phase II). This demonstrates that OxyPrem is among the top science startups in Europe.
OxyPrem 1.4 gets CE mark
September 2019
Thus, OxyPrem 1.4 may now be used in professional clinical environments. Our entire team is glad to have achieved this big milestone!
The OxyPrem 1.4 tissue oximeter system has obtained the CE mark.
OxyPrem obtains EU support
September 2019
The OxyPrem application was selected for support under phase I of the SME instrument programme following a thorough review by the European Union.
The European Union is supporting OxyPrem by means of its Horizon 2020 SME instrument. Thank you to the EU for their support!
OxyPrem in top 30 of 178 startups
September 2018
This puts OxyPrem on par with the English national team.
OxyPrem has reached the semifinals in the pitching battle of Startup Days 2018.
OxyPrem gets venture kicked
August 2018
Our team successfully completed the stage I pitch and will soon be heading for the "kickers camp" to prepare for stage II and exchange ideas with other founders. The official announcement is here.
We are now part of Switzerland's well known Venture Kick programme.